119 related articles for article (PubMed ID: 38008033)
1. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
Habringer S; Demel UM; Fietz AK; Lammer F; Schroers R; Hofer S; Bairey O; Braess J; Meier-Stiegen AS; Stuhlmann R; Schmidt-Hieber M; Hoffmann J; Zinngrebe B; Kaiser U; Reimer P; Möhle R; Fix P; Höffkes HG; Langenkamp U; Büschenfelde CMZ; Hopfer O; Stoltefuß A; La Rosée P; Blasberg H; Jordan K; Kaun S; Meurer A; Unteroberdörster M; von Brünneck AC; Capper D; Heppner FL; Chapuy B; Janz M; Schwartz S; Konietschke F; Vajkoczy P; Korfel A; Keller U
Eur J Cancer; 2024 Jan; 196():113436. PubMed ID: 38008033
[TBL] [Abstract][Full Text] [Related]
2. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Puckrin R; Chua N; Shafey M; Stewart DA
Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424
[TBL] [Abstract][Full Text] [Related]
3. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas.
Sahin U; Gokmen A; Soydan E; Urlu SM; Merter M; Gokgoz Z; Arslan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e1-e13. PubMed ID: 36344419
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Oh DH; Chua N; Street L; Stewart DA
Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
7. Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma.
Puckrin R; Sterrett R; Shafey M; Chua N; Stewart D
Transplant Cell Ther; 2022 Nov; 28(11):762.e1-762.e4. PubMed ID: 36058549
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
9. Treatment Strategies and Prognostic Factors in Secondary Central Nervous System Lymphoma: A Multicenter Study of 124 Patients.
Treiber H; Nilius-Eliliwi V; Seifert N; Vangala D; Wang M; Seidel S; Mika T; Marschner D; Zeremski V; Wurm-Kuczera R; Caillé L; Chapuy CI; Trümper L; Fischer T; Altenbuchinger M; Wulf GG; Illerhaus G; Dietrich S; Schroers R; Chapuy B
Hemasphere; 2023 Aug; 7(8):e926. PubMed ID: 37492436
[TBL] [Abstract][Full Text] [Related]
10. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
11. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T
Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752
[TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
16. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
[TBL] [Abstract][Full Text] [Related]
17. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
18. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
19. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Steinhardt MJ; Krummenast FC; Rosenwald A; Gerhard-Hartmann E; Heidemeier A; Einsele H; Topp MS; Duell J
J Cancer Res Clin Oncol; 2022 Jan; 148(1):205-214. PubMed ID: 34085097
[TBL] [Abstract][Full Text] [Related]
20. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]